Oldham R K
J Natl Cancer Inst. 1983 May;70(5):789-96.
It is clear that the rate of change in biology is rapidly accelerating. This is most apparent in the BRM area with respect to the development of new cancer therapies. New surgical approaches are being developed, and new forms of delivery for therapeutic radiation are now available. Radiosensitizers are now also being tested. Similarly, new chemotherapeutic agents and new methods of utilizing existing drugs are being developed. However, the use of BRM either alone or in combination with these other modalities is the area of greatest change and can be expected to be a major factor in achieving a greater understanding of cancer biology and a greater therapeutic specificity in the treatment of cancer patients in this decade (2, 65). Given the new technology of the 1980's, this is an exciting time. It is hoped that sufficient resources will be available to support continuing efforts to develop biologicals into effective anticancer agents. The rapidly advancing technologies of computers, cell fusion, and genetic engineering are all interrelated through the underpinnings of molecular biology to offer us unparalleled opportunities in biological research. These opportunities should translate into more effective treatments for cancer in this decade.
显然,生物学领域的变化速度正在迅速加快。这在生物反应调节剂(BRM)领域关于新型癌症治疗方法的发展方面最为明显。新的手术方法正在研发中,并且现在已有治疗性放射的新递送形式。放射增敏剂目前也在进行测试。同样,新的化疗药物以及利用现有药物的新方法也正在研发。然而,单独使用BRM或与这些其他治疗方式联合使用是变化最大的领域,并且有望成为在本十年(2, 65)对癌症生物学有更深入理解以及在癌症患者治疗中实现更高治疗特异性的一个主要因素。鉴于20世纪80年代的新技术,这是一个令人兴奋的时代。希望能有足够的资源来支持将生物制剂持续开发成有效的抗癌药物的努力。计算机、细胞融合和基因工程等迅速发展的技术都通过分子生物学的基础相互关联,为我们在生物学研究中提供了无与伦比的机会。这些机会应该会在本十年转化为对癌症更有效的治疗方法。